Panel discussion to explore the notion of treatment as prevention among people who inject drugs. Discussion will cover international and Australian contexts, touching on ethical, medical and social dimensions to treatment as prevention for this marginalised group. Panel members will include local and international experts who can provide diverse professional and personal perspectives on this important issue. The discussion will be facilitated by Australian broadcaster Ms Libbi Gorr.

Panel members include:

- The Hon Michael Kirby AC CMG
- Professor Adeeba Kamarulzaman
- Professor Michel Kazatchkine
- Mr Sam Nugraha
- Dr Niklas Luhmann
- Ms Tracy Swan
- Professor Margaret Hellard
- Facilitated by Ms Libbi Gorr

For more information please contact Elise Carrotte at elise.carrotte@burnet.edu.au or (03) 8506 2365.
Speaker Biographies

The Hon Michael Kirby AC CMG is an Australian jurist and academic, and former Justice of the High Court of Australia, serving from 1996 to 2009. In 2013 he was appointed by the President of the UN Human Rights Council to head the Commission of Inquiry on Alleged Human Rights Violations in the Democratic People’s Republic of Korea (2013-14). In 2013 he was also appointed a Commissioner of the UNAIDS Commission on Sustainable Health (2013-14). He has served on many national and international bodies, including service as a member of the World Health Organization’s Global Commission on AIDS, the UNAIDS Reference Group on HIV and Human Rights and UNDP Global Commission of HIV and the Law.

Professor Adeeba Kamarulzaman is Dean of the Faculty of Medicine and Professor of Medicine and Infectious Diseases at the University of Malaya in Kuala Lumpur. Dr Kamarulzaman has dedicated her career to the prevention, treatment and research of infectious diseases and HIV/AIDS. She is also a strong advocate for HIV prevention, treatment and care programs in marginalised communities. As President of the Malaysian AIDS Council (MAC) she successfully advocated for the introduction of evidence-based harm reduction programs to prevent HIV transmission amongst people who use drugs.

Professor Michel Kazatchkine has spent the past 30 years fighting AIDS and working to improve global health as a physician, researcher, advocate, policymaker, diplomat and administrator. He was appointed United Nations Secretary-General's Special Envoy for AIDS in Eastern Europe and Central Asia in July 2012. From 2007 to 2012 he served as the Executive Director of the Global Fund to fight AIDS, Tuberculosis and Malaria and from 1998 to 2005 he was Director of the French National Agency for AIDS Research. Between 2005 and 2007 he served as France's Global Ambassador for HIV and Communicable Diseases.

Mr Sam Nugraha has worked for UNAIDS Indonesia since 2003, focusing on treatment literacy, access to treatment and capacity building. Previously, he worked for seven years as a counsellor in drug-using communities, building his involvement on his own personal experience related to drug use and the HIV epidemic. The Indonesian Network for People who Use Drugs elected Sam as National Coordinator in 2009 until 2011. In 2013-2014 he served ANPUD as Regional Coordinator. In 2010, Sam initiated Rumah Singgah PEKA, a halfway house for people who use drugs.

Dr Niklas Luhmann is a medical doctor and completed his Master of Science (Msc) in International Public Health at the University of Berlin and Copenhagen in 2006. He has been working for many years on access to healthcare of key populations and focuses today on issues around HIV and hepatitis C prevention, treatment and care access of drug user populations. He joined the French NGO Médecins du Monde (MdM) in 2005 and is today working as Harm Reduction and HIV/AIDS advisor for MdM at the headquarters in Paris. For the past two years, he has worked increasingly on issues related to hepatitis C treatment access of drug user populations.

Ms Tracy Swan, an HIV/AIDS activist since 1990, has been a direct service provider at HIV clinics, syringe exchange and drug treatment programs, methadone clinics and homeless shelters. She has worked extensively with people living with, or at risk of, HIV and hepatitis C. Tracy joined Treatment Action Group in 2003. She continues to work with other activists, U.S. and European regulators, researchers and pharmaceutical industry representatives to monitor clinical trial design, as well as to establish regulatory guidance for hepatitis C drug development.

Professor Margaret Hellard’s work centres on infectious diseases, preventing their transmission and identifying the impact of these infections in vulnerable populations. A researcher and clinician, her principal research interests include the epidemiology of hepatitis C, HIV and hepatitis B. She has considerable experience in undertaking community-based research and interventions involving people who inject drugs, young people, vulnerable populations and experience in research in tertiary care institutes.